Table 2

Predictors of mortality in CTD-PAH on univariate analysis

Variable

Unadjusted HR (95% CI)

P

Male sex

3.42 (1.27 to 9.22)

0.02

Age at PAH diagnosis, years

1.01 (0.98 to 1.04)

0.72

Underlying CTD (SSc)

1.27 (0.44 to 3.66)

0.66

WHO FC at baseline

3.64 (1.32 to 10.01)

0.01

Baseline 6MWD*

0.70 (0.52 to 0.95)

0.02

Pericardial effusion

2.83 (1.12 to 7.12)

0.03

mPAP at baseline, mmHg

1.01 (0.98 to 1.05)

0.42

mRAP at baseline, mmHg

1.11 (1.02 to 1.19)

0.01

Warfarin therapy

0.26 (0.11 to 0.66)

0.004

Combination therapy

0.38 (0.16 to 0.92)

0.03

*hazard ratio relates to each 100 metres increase in 6MWD

6MWD, six minute walk distance; CTD, connective tissue disease; HR, hazard ratio; mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; SSc, systemic sclerosis; WHO FC, World Health Organization Functional Class

Ngian et al. Arthritis Research & Therapy 2012 14:R213   doi:10.1186/ar4051